Offin, M., Zeng, X., Wang, S., Xie, B., Marmarelis, M. E. (2026). Volrustomig, a novel bispecific PD-1/CTLA-4 monoclonal antibody, as single-agent first-line therapy for unresectable pleural mesothelioma: Substudy 5 of the eVOLVE-02 phase 2 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8126